Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177lu-rosopatamab
- Development stage
- Phase 3
- Lead developer
- Telix Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Mechanism of Action:** Lutetium-177 rosopatamab is a radiopharmaceutical consisting of a fully human monoclonal antibody (rosopatamab) targeting prostate-specific membrane antigen (PSMA), conjugated to the beta-emitting radioisotope lutetium-177 via a DOTA chelator. The antibody binds specifically to PSMA-expressing tumor cells and delivers targeted radiation directly to these cells and their metastases. This approach aims to maximize tumor cell killing while minimizing damage to normal tissues[1][3][5]. **Primary Indication:** Developed for the treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). It is currently being investigated in combination with standard-of-care therapies such as abiraterone, enzalutamide, or docetaxel[1][9]. **Development Status:** Phase III clinical trials are ongoing for mCRPC in multiple countries. The drug has shown promising efficacy and safety in early-phase studies[1][3][4].
- Brand names
- None
- Other names
- 177Lu-DOTA-rosopatamab177Lu-DOTA-TLX591177Lu-DOTA-TLX591-CHOLutetium 177 rosopatamab tetraxetanLutetium177 rosopatamab tetraxetanLutetium-177 rosopatamab tetraxetan
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 177lu-rosopatamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177lu-rosopatamab.